t-dxd demonstrates high levels of efficacy in patients with her2 unresectable and/or mbc previo...
Published 1 year ago • 92 plays • Length 7:12Download video MP4
Download video MP3
Similar videos
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
5:26
trastuzumab deruxtecan shows benefit in patients with her2 mbc
-
3:09
destiny-breast02: high levels of efficacy of t-dxd in previously treated her2 breast cancer
-
2:02
dr tarantino on updated survival data with t-dxd in her2 breast cancer
-
12:47
trastuzumab deruxtecan vs trastuzumab emtansine in patients with her2 metastatic breast cancer
-
5:09
trastuzumab deruxtecan shows benefit across her2 metastatic breast cancer subgroups
-
6:06
combining anti-her2 agents with immunotherapy for her2 mbc
-
2:30
destiny-breast04: t-dxd in her2-low breast cancer regardless of molecular markers
-
1:08
updated survival results of destiny-breast03: t-dxd vs t-dm1 in her2 metastatic breast cancer
-
2:38
highlights on t-dxd in pretreated her2-expressing solid tumours : the destiny-pantumor02 study
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
4:42
t-dm1 may extend pfs among patients with unresectable locally advanced or metastatic her2-positi...
-
4:15
debbrah: t-dxd in her2 or her2-low advanced breast cancer with cns involvement
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
5:59
trastuzumab deruxtecan for the treatment of her2 breast cancer
-
2:41
dr tarantino on the safety of t-dxd and t-dm1 in her2 breast cancer
-
1:08
destiny-breast02: t-dxd in her2 metastatic breast cancer previously treated with t-dm1
-
1:17
comment: phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer pts
-
1:06
incorporating t-dxd in patients with her2 or her2-low bc and leptomeningeal carcinomatosis